TRVI

Analyst Note: Trevi Therapeutics, Inc. (TRVI)

Date: 2026-06-20 Event Date: 2026-06-20

1. Structural Readiness

• Setup State: Actionable (Forming Coil)
• Conservative Entry: Not yet triggered (awaiting confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: Current price of $17.21 represents a partial entry opportunity for traders willing to accept the risk of a forming coil, though the setup is not yet fully actionable on a conservative basis.
• Breakout Level: Pending confirmation above the coil resistance.
• Current Price: $17.21.
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 4.7% (High). This indicates elevated volatility, which is consistent with the "High" bucket (4–6%) often seen in clinical-stage biotech setups. This volatility suggests significant price movement potential but requires careful position sizing.

2. Thesis Layer

• Primary Secular Thesis: Biotech & GLP-1 → Rare & Orphan.
• Directness: Direct. Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) specifically for chronic cough in patients with Idiopathic Pulmonary Fibrosis (IPF), non-IPF Interstitial Lung Disease (ILD), and Refractory Chronic Cough (RCC).
• Thesis Weighting: The company is a pure-play beneficiary of the "Rare & Orphan" theme within the broader Biotech sector. The focus on unmet needs in IPF and RCC (affecting 2-3 million adults in the U.S.) aligns with the high-value, low-competition dynamics typical of orphan drug development. The "Biotech & GLP-1" label in the thesis membership likely reflects the broader market's appetite for metabolic and respiratory therapies, though Trevi's core mechanism (nalbuphine) is distinct from GLP-1 agonists. The direct exposure to the orphan drug pipeline provides a strong conviction anchor, as regulatory pathways for rare diseases often offer clearer routes to approval and pricing power.

3. Business Overview

Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio (oral nalbuphine ER) for the treatment of chronic cough. The company's business model relies on advancing its proprietary opioid antagonist through clinical trials to secure FDA approval for specific indications, followed by commercialization.

Key Business Milestones & Evidence (as of 2026-06-20):

• Clinical Progress: Management expects to initiate the first of two Phase 3 trials in the second quarter of 2026 and the second Phase 3 trial in the second half of 2026. (Source: E8, E17).
• Trial Design: The first Phase 3 trial is planned to enroll approximately 300 patients with 52 weeks of fixed dosing (54 mg BID), with the primary endpoint at 24 weeks. (Source: E16).
• Secondary Indications: The company plans to initiate an adaptive Phase 2b trial for non-IPF ILD-related chronic cough in the second half of 2026, subject to FDA review. (Source: E10, E19). Additionally, a Phase 2b parallel arm dose-ranging trial for Refractory Chronic Cough (RCC) is expected to initiate this quarter (Q2 2026). (Source: E3).
• Data Readouts: Management expects topline results from the first Phase 3 trial in the first half of 2028 and from the second Phase 3 trial in the second half of 2027. (Source: E9). Topline results from the Phase 2b RCC trial are expected in the second half of 2027. (Source: E11).
• Regulatory Alignment: An End-of-Phase 2 meeting with the FDA was completed, resulting in overall alignment on the plan for remaining clinical studies to support an NDA submission. (Source: E23).
• Financial Runway: Management has extended its cash runway into 2030, which includes funding for the IPF-related chronic cough development program potentially through FDA approval. (Source: E5, E6).
• Intellectual Property: A core method of treatment patent for IPF-related chronic cough was issued in Europe in Q2 2026, providing protection through 2039. (Source: E7).
• Prior Efficacy: The Phase 2b CORAL trial achieved its primary efficacy endpoint, showing statistically significant reductions in 24-hour cough frequency (60.2% reduction at 108 mg BID vs. 16.9% placebo). (Source: E14, E15).

4. Archetype and Conviction

• Archetype: Growth Leader.
• Fit: The company fits the "Growth Leader" archetype due to its progression through late-stage clinical trials (Phase 3 initiation) and the potential for significant market expansion in the chronic cough space. The "Growth" aspect is driven by the binary nature of clinical readouts and the potential for commercialization in large addressable markets (IPF, RCC).
• Valuation Context: While specific valuation multiples are not provided in the evidence, the extended cash runway to 2030 suggests a capital-efficient structure that supports long-term growth without immediate dilution pressure. The "Small" cap bucket classification indicates a higher risk/reward profile typical of clinical-stage biotechs.
• Conviction Stack:
• Thesis Strength: High. Direct exposure to a high-unmet-need orphan drug market.
• Evidence Quality: Strong. Multiple primary sources (earnings transcripts, SEC filings) confirm a clear, aligned regulatory path and robust clinical data from Phase 2b.
• Structural Quality: Moderate to High. The "Forming Coil" setup suggests accumulation, but the high ATR (4.7%) indicates volatility. The setup is not yet confirmed, requiring a breakout for full validation.
• Rerating Potential: Significant. Successful initiation of Phase 3 trials and subsequent positive readouts in 2027-2028 could drive substantial re-rating.

5. Invalidation, Strengthening, and Gaps

• Strengthening: A confirmed breakout above the coil resistance (price breaking out of the consolidation range) would strengthen the setup. Positive topline data from the Phase 2b RCC trial (if released early) or successful enrollment milestones in Phase 3 would also strengthen the case.
• Gaps in Evidence:
• Cash Burn Rate: While the runway is extended to 2030, the specific quarterly burn rate and cash balance as of June 2026 are not detailed in the provided evidence.
• Competitive Landscape: No specific evidence regarding competitive therapies in the chronic cough space is provided, which is a key risk factor for market share.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management extended cash runway to 2030; FDA alignment achieved for Phase 3 NDA plan; Phase 2b CORAL trial showed statistically significant efficacy (60.2% reduction vs 16.9% placebo); Phase 3 trials scheduled to initiate in Q2 and H2 2026. Sizing hint: Position size should be reduced relative to confirmed breakouts due to the "forming" status and high volatility; treat as a partial position until breakout confirmation. Expected path: Price consolidates in the current range while management executes Phase 3 initiation; potential for volatility spikes around trial enrollment updates; breakout likely if trial initiation proceeds as planned. Expected horizon: 6 to 12 months for setup confirmation; 24 to 36 months for clinical data readouts.